ArticleFrontiers in oncology2026
Exploring the molecular mechanism of Coptis-cinnamon in combating gastric cancer via the MAPK Pathway based on network pharmacology.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) ranks as the fifth most common malignancy worldwide. Current treatments are limited by side effects and drug resistance, highlighting the need for novel therapies. Traditional Chinese medicine (TCM) pair Coptis-Cinnamon (HL-RG) shows promise against GC, but its mechanism remains unclear. Methods: Active components and targets of HL-RG were obtained from TCMSP, and GC-related genes from GEO and GeneCards. Intersection targets were analyzed via STRING for PPI network construction. GO and KEGG enrichment analyses were performed using DAVID to identify key pathways and hub genes. Clinical relevance, mutations, immune infiltration, and drug sensitivity were analyzed. Molecular docking validated interactions between core components and hub genes. Results: Sixteen active components and 499 targets of HL-RG were identified, with 55 common targets screened from 3,194 GC-related DEGs. Enrichment analyses revealed involvement in inflammatory responses and the MAPK pathway, identifying PDGFRB, EGFR, MMP2, MMP9, and KIT as hub genes. Molecular docking showed binding affinities between core components (berberine, berberrubine) and hub genes. Conclusions: HL-RG exerts anti-GC effects by targeting the MAPK pathway and its hub genes, providing a scientific basis for its clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.